ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Stock Chart & Stats
$21.74
-$0.09(-0.52%)
At close: 4:00 PM EST
$21.74
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$14.08 - $28.35
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.77M
Market Cap
$3.71B
Enterprise Value$3.58B
Total Cash (Recent Filing)$819.69M
Total Debt (Recent Filing)$52.19M
Price to Earnings (P/E)11.6
Beta1.11
Next Earnings
May 13, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.60
Shares Outstanding170,494,610
10 Day Avg. Volume1,369,877
30 Day Avg. Volume1,770,477
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue3.34
Enterprise Value/Gross Profit3.64
Enterprise Value/Ebitda27.25
Forecast
1Y Price Target
$31.93Price Target Upside46.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.45
Revenue Forecast (FY)$1.25B
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionAn expanded salesforce for Nuplazid and Daybue STIX is expected to increase coverage of key prescribers and broaden patient reach, supporting sustained commercial momentum.
Pipeline ReadoutsA pivotal clinical readout for remlifanserin in Alzheimer's psychosis could provide meaningful upside if it demonstrates efficacy and a safety profile similar to Nuplazid, offering clinicians a safer on‑label alternative to current antipsychotics.
Product Formulation And Patient AccessA powder formulation of Daybue STIX is expected to improve tolerability and broaden patient access by addressing volume, taste, and excipient‑related gastrointestinal issues that limited the liquid version.
Bears Say
European Regulatory RiskA negative opinion from a European regulator and the need for re‑examination could delay or lower the chance of trofinetide and Daybue approvals in the EU, creating uncertainty for international revenue.
Rebate Headwinds And Revenue PressureLarger‑than‑expected rebate expenses have weakened reported Nuplazid sales and can obscure underlying demand strength, pressuring near‑term revenue results.
Rising Operating ExpensesProjected increases in selling, general and administrative expenses and research and development spending are larger than analysts expected, creating near‑term cost pressure on profitability.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $14.08 and its highest was $28.35 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $3.71B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is May 13, 2026 which is in 31 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Feb 25, 2026. The company reported $1.6 earnings per share for the quarter, beating the consensus estimate of $0.137 by $1.463.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.06.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 170,494,610 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $1.6 in its last earnings report, beating expectations of $0.137. Following the earnings report the stock price went down -1.322%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.93 (46.87% Upside)
$31.93 (46.87% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 149.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.07%
12-Months-Change
Fundamentals
Return on Equity
41.90%
Trailing 12-Months
Asset Growth
31.69%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear growth drivers: record adjusted revenue (> $1 billion), double-digit growth for both NUPLAZID and DAYBUE, an approved new DAYBUE formulation (STIX) with early traction, meaningful pipeline catalysts (remlifanserin Phase II readout in Aug–Oct 2026 and multiple planned study initiations), and a solid cash position. Offsetting these positives were industry- and company-specific risks: a negative CHMP trend vote for trofinetide in the EU creating regulatory uncertainty, a nonrecurring $20M IRA-related net sales adjustment plus cash outflows from IRA invoices, and a notable step-up in SG&A that will pressure near-term margins. On balance, the highlights — notably strong top-line growth, product launches, pipeline catalysts, and healthy cash — outweigh the lowlights, which are largely regulatory and timing risks.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$31.93
▲(46.87% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
Currently, No data available
---